Description

Tempus AI’s $1.6 Billion Outlook Meets a New Challenge — Can Reimbursement Keep Up?

Tempus AI, Inc. reported third quarter 2026 results demonstrating continued revenue growth alongside strategic partnerships and operational progress, positioning the company within a competitive oncology diagnostics and data analytics market. Total revenue reached $412 million, marking a 23% year-over-year increase, driven by a 20% growth in diagnostics and a 33% uptick in the Data and Applications segment. Within diagnostics, oncology revenues rose 28% fueled by a 32% increase in unit volume, while hereditary cancer testing contributed $111 million despite moderated growth compared to previous quarters. The data business grew notably through expanded long-term collaborations with biopharma companies such as Bristol Myers Squibb, Moderna, and Merck, indicating increasing demand beyond oncology into areas like Alzheimer’s disease.